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γ-Secretase is a four subunit, 19-pass transmembrane enzyme that cleaves amyloid
precursor protein (APP), catalyzing the formation of amyloid beta (Aβ) peptides that form
amyloid plaques, which contribute to Alzheimer’s disease (AD) pathogenesis. γ-Secretase
also cleaves Notch, among many other type I transmembrane substrates. Despite its
seemingly promiscuous enzymatic capacity, γ-secretase activity is tightly regulated.
This regulation is a function of many cellular entities, including but not limited to
the essential γ-secretase subunits, nonessential (modulatory) subunits, and γ-secretase
substrates. Regulation is also accomplished by an array of cellular events, such as
presenilin (active subunit of γ-secretase) endoproteolysis and hypoxia. In this review we
discuss how γ-secretase is regulated with the hope that an advanced understanding of
these mechanisms will aid in the development of effective therapeutics for γ-secretase-
associated diseases like AD and Notch-addicted cancer.
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INTRODUCTION
γ-Secretase is an intramembrane aspartyl protease that cleaves
an array of type 1 transmembrane substrates, of which amyloid
precursor protein (APP) and Notch are the most widely studied.
APP undergoes sequential proteolytic processing by β-secretase
(BACE1) and γ-secretase to generate amyloid beta (Aβ) peptides,
which are 37–43 amino acids long. Notch, a protein that resides
on the surface of signal-receiving cells as a heterodimeric receptor,
is also subject to a series of proteolytic cleavages (Figure 1).
The scientific scrutiny sustained by both APP and Notch results
from their role in disease: aberrant γ-secretase cleavage of APP
and Notch can lead to Alzheimer’s disease (AD) and cancer,
respectively. γ-Secretase is an important potential drug target for
both diseases and γ-secretase inhibitors (GSIs) and modulators
(GSMs) are currently in clinical trials.
Biochemical studies indicated that γ-secretase activity is cat-
alyzed by the presenilin (PS)-containing macromolecular com-
plex (Li et al., 2000a). The search for other components of
the complex revealed three additional proteins: nicastrin (Nct),
anterior pharynx-defective-1 (Aph-1), and presenilin enhancer-2
(Pen-2) (Yu et al., 2000; Francis et al., 2002; Goutte et al.,
2002). It has since been established that these four pro-
teins constitute the mature γ-secretase complex (De Strooper,
2003; Selkoe and Wolfe, 2007), and their stepwise assembly,
followed by endoproteolysis of PS into amino-terminal (PS-
NTF)and carboxy-terminal fragments (PS-CTF), is necessary for
active complex formation (Takasugi et al., 2003) (Figure 2).
The recent report of a 4.5Å cryo-electron microscopy struc-
ture of intact human γ-secretase and identification of novel
γ-secretase modulating mechanisms have provided insight into
the flexibility and complexity of this enzyme (Lu et al.,
2014).
γ-Secretase processing of its substrates produces distinct
amino and carboxy termini with variable functions; some prod-
ucts of γ-secretase cleavage function as transcriptional regulators
while others are thought to play roles in signaling, cell adhesion,
and cytoskeletal dynamics. As the list of putative γ-secretase
substrates continues to grow, now reaching over 90 reported
proteins (Haapasalo and Kovacs, 2011), the lack of homology
between these substrates becomes increasingly apparent: other
than the fact that they are all type I transmembrane proteins
that have undergone ectodomain shedding, γ-secretase substrates
are surprisingly dissimilar (Beel and Sanders, 2008; Lleó, 2008)
(of note, how many of these substrates are actually processed
by γ-secretase in vivo remains to be investigated). Not only
are the substrates themselves widely variable, but cleavage of
some substrates (i.e., CD44 and Notch-1) (Lammich et al., 2002;
Okochi et al., 2002) leads to release of peptides with variable
carboxy-terminal ends, further confirming γ-secretase’s astound-
ing promiscuity. In short, γ-secretase not only cleaves many
substrates, but it cleaves the same substrate in many places. The
permutation is daunting, and may be evolutionary evidence for
γ-secretase’s initial function in regulated degradation of trans-
membrane proteins (Kopan and Ilagan, 2004). However, even if
γ-secretase was ever simply a “proteasome of the membrane,”
its function now is certainly much more complex. As a result,
γ-secretase regulation must be at least as intricate and diverse as
its function.
Frontiers in Aging Neuroscience www.frontiersin.org January 2015 | Volume 6 | Article 342 | 1
Gertsik et al. Regulation of γ -secretase
FIGURE 1 | Proteolytic processing of APP and Notch. Mature Notch
receptors are activated by binding to ligands (Jagged-1, -2 and Delta-like -1,
-3, and -4) located on adjacent signal-presenting cells. An induced
conformational change exposes a cleavage site (S2) for ADAM family
metalloproteases that cleave Notch at an extracellular, membrane-proximal
region. The membrane-bound Notch segment that results from this
cleavage, known as Notch Intracellular Truncation domain (NEXT), is a
γ-secretase substrate (Kopan and Ilagan, 2009). γ-Secretase performs the
subsequent cleavage at S3 (De Strooper et al., 1999), releasing Notch
intracellular domain (NICD) from the membrane and allowing for signal
transduction through binding with the CBL-1, Su(H), Lag-1 (CSL; Schroeter
et al., 1998; Struhl and Adachi, 1998) family of DNA binding proteins. APP
undergoes sequential proteolytic processing first by β-secretase (BACE1,
aspartyl protease) and then by γ-secretase, in the amyloidogenic pathway.
The first cleavage results in ectodomain shedding in which the
amino-terminal of APP is removed, yielding a soluble APP derivative
(sAPPβ) and a carboxy-terminal membrane stub known as βCTF (C99). βCTF
is a substrate for γ-secretase, and is cleaved in its transmembrane domain
to form AICD and the potentially toxic Aβ. Mutations in presenilin (the
catalytic subunit of γ-secretase) and APP can lead to increases in the Aβ42
to Aβ40 ratio, resulting in Aβ deposition and plaque formation.
γ-Secretase activity is regulated by the assembly of its four
essential subunits as well as at the level of the entire com-
plex. Extensive investigation of the former revealed that each of
the four essential γ-secretase subunits is tightly and indepen-
dently controlled. More recently, the importance of regulation
of the entire complex has emerged, suggesting additional lev-
els of modulation in γ-secretase function. CD147, phospholi-
pase D1, TMP21, GPR3, γ-secretase activating protein (GSAP),
syntaxin-1, Arc, voltage-dependent anion channel 1 (VDAC1),
contactin-associated protein 1 (CNTNAP1), TPPP, NDUFS7,
Erlin-2, β-arrestin-1, β-arrestin-2, Hif-1α and Nexin 27 have
all been implicated as nonessential γ-secretase interacting part-
ners that modulate γ-secretase activity (Zhou et al., 2005; Cai
et al., 2006; Chen et al., 2006; Thathiah et al., 2009; He et al.,
2010; Teranishi et al., 2010; Wu et al., 2011; Frykman et al.,
2012; Hur et al., 2012; Teranishi et al., 2012; Liu et al., 2013;
Thathiah et al., 2013; Villa et al., 2014; Wang et al., 2014).
However, some of this work is controversial and it remains to
be seen whether many of these proteins play a specific and
functionally significant role in γ-secretase regulation (Vetrivel
et al., 2007, 2008; Hussain et al., 2013). Despite the uncertainty,
much can be learned from the way in which a promiscuous
enzyme is spatially and temporally modulated by its nonessential
cofactors.
We begin by discussing the four essential subunits of
γ-secretase, their physiological roles, and, where known, the way
in which they regulate γ-secretase activity. Next we move to
γ-secretase modulation by nonessential γ-secretase interacting
partners, in particular GSAP and Hif-1α, which have been con-
vincingly shown to specifically engage with the active γ-secretase
complex. Last we comment on γ-secretase’s regulation by its
substrate, APP.
γ-SECRETASE IS REGULATED BY ITS FOUR ESSENTIAL
SUBUNITS
γ-Secretase’s enzymatic promiscuity may on first glance sug-
gest a kind of rampant cleavage activity that indiscriminately
chops up anything in its way. Actually, the opposite is true.
γ-Secretase may be flexible in its choice of substrate and cleav-
age site, but its activity is controlled in the cell by a variety
of mechanisms, not the least of which is regulation of active
complex formation. Perhaps the most basic evidence for this is
the finding that γ-secretase activity cannot be increased through
the overexpression of PS alone (Levitan et al., 2001), and can
be reconstituted only when all four γ-secretase subunits are
present (Edbauer et al., 2003). Put another way, the selective
ablation of any one of the essential subunits leads to a loss
of active complex and enzymatic activity (De Strooper, 2003).
This implies that each subunit must be in the proper place
and time if there is to be any hope for γ-secretase formation.
However, the presence of all four essential subunits does not
guarantee active complex formation. This is evidenced by the
fact that only a small fraction of steady-state γ-secretase in the
cell is actually catalytically active (Beher et al., 2003; Lai et al.,
2003; Gu et al., 2004). Furthermore, while overexpression of
wild type PS1 in mice is sufficient to increase the amount of
γ-secretase complex and protease activity in brains, this is not
the case in cellular studies (Li et al., 2011). The implication
is that even when all four subunits are in complex with one
another, additional events may be necessary to render that com-
plex catalytically active. Some of these events are discussed in the
“γ-secretase is regulated by modulatory proteins” section of this
review.
The issue is further complicated by the fact that active com-
plexes fall into a wide range of activities with respect to both
catalytic efficiency and substrate specificity. Despite the decep-
tive language used here to describe γ-secretase as “active” and
“inactive,” γ-secretase activity is far from a simple on/off switch.
Let’s look at the statistics: assuming γ-secretase complexes have
a 1:1:1:1 ratio of all essential subunits (Sato et al., 2007), at
least four different complexes can be theoretically constructed,
keeping in mind the existence of PS and Aph-1 (PS1/PS2 and
Aph-1a/Aph-1b) isoforms and the finding that these isoforms do
not co-exist in the same complexes (Lai et al., 2003; Shirotani
et al., 2004). Identification of the Aph-1a splice variants (Aph-
1aS and Aph-1aL) increased the permutation further, to a total of
six (Shirotani et al., 2004). Experimentally, different γ-secretase
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FIGURE 2 | γ-Secretase complex formation and regulatory roles of
individual essential subunits. The γ-Secretase complex is formed by the
sequential assembly of Aph1, nicastrin, presenilin, and Pen-2. First, Aph-1 and
nicastrin come together to form the scaffold. Next, full length presenilin is
incorporated. Last, Pen-2 is recruited and full length presenilin is
endoproteolysed into presenilin-NTF/CTF, activating the enzyme. Nicastrin, a
heavily glycosylated single-pass transmembrane protein, plays a role in
scaffolding, enzyme stabilization, substrate recognition, and trafficking.
Nicastrin’s amino acids 312–340 are important for substrate recognition and
deletion of these residues reduces γ-secretase activity and nicastrin’s
interaction with APP and Notch. Furthermore, mutation of nicastrin’s C213
and C230 leads to different impact on processing of APP and Notch,
underscoring nicastrin’s role in substrate selectivity. Aph-1, a 7-pass
transmembrane protein with 3 human isoforms, is crucial for scaffolding and
stability, and may have an additional role in determining length of Aβ species
produced depending on which isoform is incorporated into the γ-secretase
complex. The GXXXG motif in Aph-1 is critical for γ-secretase complex
assembly. Presenilin, a 9-pass transmembrane protein with 2 isoforms, is the
catalytic subunit of γ-secretase, and full length presenilin is a zymogen that
must be endoproteolysed into NTF/CTF to be enzymatically active. Mutations
in presenilin1 and presenilin2-encoding genes account for the majority of
genetic mutations leading to Familial Alzheimer’s disease. Pen-2, a 2-pass
transmembrane protein, is required for presenilin endoproteolysis and
γ-secretase activation, but also may play an endoproteolysis-independent role
in γ-secretase regulation. Active γ-secretase constitutes a small percentage
of total γ-secretase and resides primarily in the plasma membrane.
complexes have indeed been identified and shown to vary in
catalytic activity (Lai et al., 2003). Some tissue specificity has
been observed in the expression of Aph-1 and PS variants,
but this alone cannot account for determining which com-
plex gets formed and which does not, especially since different
variants of the γ-secretase complex exist dynamically in the
same tissue, and even in the same cell line (Placanica et al.,
2009a,b). More complicated mechanisms of regulating complex
formation pervade, such as the ability of one isoform/mutant
to outcompete the other for limiting factors (Placanica et al.,
2009a).
The inherent complexity of γ-secretase can be put into per-
spective by comparing it to signal peptide peptidase (SPP), the
only other family of intramembrane aspartyl proteases. Unlike
γ-secretase, SPP appears to function alone without the par-
ticipation of other protein co-factors (Weihofen et al., 2002),
although it does form higher order oligomers (Nyborg et al.,
2004, 2006; Miyashita et al., 2011). SPP’s simpler structure fits
its function as a processor of signal peptides in the mem-
brane, which may not require the same extent of regulation as
γ-secretase. Below we discuss each essential γ-secretase subunit
individually, paying particular attention to its role in regulating
activity.
PRESENILIN
PS1 and and its less abundant isoform PS2, are ∼50 kDa mul-
tipass transmembrane proteins that contain the catalytic core
of the γ-secretase complex. These proteins were implicated in
γ-secretase function when knock-out of PS1 resulted in severely
reduced γ-secretase activity (De Strooper et al., 1998). For a
long time it was unclear whether PS contains the active site of
γ-secretase or is a chaperone involved in γ-secretase activity or
colocalization to substrate. Several critical studies indicated that
PS is indeed the catalytic subunit of γ-secretase. First, mutation
of the two conserved aspartates in both PS1 (Wolfe et al., 1999)
and PS2 (Steiner et al., 1999) significantly reduced Aβ production,
suggesting that the aspartates are catalytic or essential residues
for γ-secretase activity. Second, aspartyl protease transition-state
analogs were shown to directly label and inhibit γ-secretase
activity through covalent binding to PS, providing compelling
evidence for PS as the catalytic core of γ-secretase (Esler et al.,
2000; Li et al., 2000b). Finally, recombinant PS reconstituted
into proteoliposomes was shown to be catalytically active even in
the absence of other γ-secretase subunits (in contrast to cellular
activity which requires all four subunits), providing conclusive
evidence for PS’s role as the catalytic subunit of γ-secretase (Ahn
et al., 2010).
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PS is synthesized as a full length (FL) protein but PS-FL
is unstable and is quickly either endoproteolysed or degraded
(Ratovitski et al., 1997; Thinakaran et al., 1997; Zhang et al.,
1998). Endoproteolysis, a process required for γ-secretase acti-
vation, results in the formation of PS1 amino-terminal and
carboxy-terminal fragments (PS1-NTF/CTF), which remain asso-
ciated as a stable heterodimer (Podlisny et al., 1997). In fact,
the requirement for endoproteolysis is an onerous one to meet,
as evidenced by the fact that in cells it is dependent on the
assembly of all four subunits. Furthermore, the ability of FAD
mutant PS1∆E9 (Thinakaran et al., 1996) to be constitutively
active despite its inability to be endoproteolysed suggests that
evolution has found a way to increase enzymatic activity by
circumnavigating an important requirement. A parallel can again
be drawn to the PS-like enzyme SPP, which is not endoprote-
olysed and is active in its FL form, suggesting a simpler form
of regulation. The exact molecular mechanism of γ-secretase
endoproteolysis remains unclear, but one approach to study it
is through the use of active-site directed probes (Gertsik et al.,
2014).
As mentioned previously, the formation of an active complex
is only the first hurdle in regulating γ-secretase activity in the
cell. An added layer of regulation resides in the choice to form
PS1 vs. PS2-containing complexes. Different PS variants play
different, albeit overlapping, roles as evidenced by genetic knock
out studies (De Strooper et al., 1998; Herreman et al., 1999). Later
biochemical studies showed that PS1 complexes display a much
higher activity than PS2 complexes for a truncated APP substrate
(Lai et al., 2003).
PS1 is not only the more active of the two isoforms, but
also may be the more amyloidogenic. A reconstitution study
in which four γ-secretase isoforms (PS1–aph-1a, PS1–aph-1b,
PS2–aph-1a, PS2–aph-1b) were analyzed showed that PS1 com-
plexes form more aggregation-prone Aβ42 (relative to Aβ40)
compared to PS2 complexes (Lee et al., 2011). This provides
further evidence that the 67% homologous PS isoforms may
have different cleavage-site preferences. It would be interesting to
investigate whether the PS isoforms also have different substrate
preferences. For example, do PS1/PS2 complexes differentially
cleave APP/Notch? The decision to form PS1 vs. PS2 complexes
probably determines not only “how much” but also “what” is
cleaved.
PEN-2
Pen-2, a ∼10 kDa protein with two TMDs (Crystal et al., 2003),
was discovered as a gene product that can interfere with PS
activity in a genetic study involving C. elegans (Francis et al.,
2002). Pen-2 is required for endoproteolysis of PS-FL into PS-
NTF/CTF and for γ-secretase activity. The following evidence
supports that Pen-2 is indispensable for endoproteolysis of PS:
first, knock-down of Pen-2 by RNAi resulted in a decrease of PS1-
NTF/CTF and a stabilization of the PS1 holoprotein in the Nct-
Aph-1 complex, while transient overexpression of Pen-2 in Pen-2
deficient cells led to the recovery of PS fragments (Takasugi et al.,
2003). Second, coincorporation of recombinant PS1 and Pen-2
in liposomes showed Pen-2 to be necessary and sufficient for
endoproteolysis of PS1 (Ahn et al., 2010). Pen-2 is also required
for γ-secretase activity: Pen-2 knockdown in mammalian cells
resulted not only in an accumulation of the PS1 holoprotein, but
also in a drastic decrease in γ-secretase activity (Takasugi et al.,
2003). Pen-2−/− mouse embryos exhibited a Notch-deficiency
phenotype and Pen-2−/− MEFs displayed no γ-secretase activity
toward APP processing (Bammens et al., 2011). Furthermore,
overexpression of human Pen-2 in Pen-2 deficient mice recapit-
ulated AD-like symptoms such as increase in Aβ42, behavioral
dysfunctions, and feeding defects, underscoring the importance
of Pen-2 in γ-secretase activity and AD pathogenesis (Nam et al.,
2011).
The roles of Pen-2 in PS endoproteolysis and γ-secretase
activity raised the question—is Pen-2 necessary for γ-secretase
activity per se, or is Pen-2-inspired endoproteolysis of PS the
only requirement for activity? To answer this question the cat-
alytically active PS1∆E9 endoproteolysis deficient mutant was
expressed in Pen-2−/− MEFs and found to have no activity,
suggesting that Pen-2 is required for γ-secretase activity per
se, and not just for endoproteolysis of PS (Bammens et al.,
2011). This implies that Pen-2 regulates γ-secretase on mul-
tiple levels. We already discussed that Pen-2 dictates activity,
as PS-FL is a zymogen that relies on Pen-2-dependent endo-
proteolysis. This type of regulation is close to being an “on”
switch, since lack of WT PS endoproteolysis precludes γ-secretase
activity. However, Pen-2 is also capable of more subtle regula-
tion in which it modulates the composition of the γ-secretase
complex: overexpression of Pen-2 shifted the equilibrium from
PS1 containing complexes to PS2 containing complexes and
increased the Aβ42:Aβ40 ratio (Placanica et al., 2009a). Clearly,
Pen-2 regulates γ-secretase through a variety of mechanisms,
not the least of which are endoproteolysis of PS and complex
assembly.
NICASTRIN
In the search for cofactors required for γ-secretase activity, Nct,
a type I transmembrane glycoprotein, was the first to be dis-
covered through coimmunoprecipitation with PS1-directed anti-
body (Yu et al., 2000). A 1.95 Å-resolution crystal structure
of Nct from an amoeboid eukaryote Dictyostelium purpureum
has been solved (Xie et al., 2014). Four hydrophilic residues in
the proximal one third of the N-terminal portion of the Nct
TMD are critical for interaction between Nct and the rest of the
γ-secretase complex (Capell et al., 2003). Nct interacts initially
with Aph-1, followed by the incorporation of PS and Pen-2
(LaVoie et al., 2003). Not only does Nct, together with Aph-
1, provide a scaffold for the γ-secretase complex, but it also
may recognize γ-secretase substrates by binding to their amino
termini. Particularly, Nct’s ectodomain has been shown to bind
the extracellular regions of APP and Notch after they undergo
ectodomain shedding, with Nct’s residues 312–340, and especially
Glu333, being most important for substrate recognition (Shah
et al., 2005). This finding branded Nct as the substrate-recruiting
subunit of γ-secretase. Further confirmation came from work
with anti-Nct antibodies: the monoclonal antibody A5226A binds
the extracellular domain of Nct causing both a disruption in
Nct binding to Notch-based substrate (N100) and a decrease in
γ-secretase activity (Hayashi et al., 2011). Additionally, the use
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of synthetic antibodies showed that a certain structured region
in Nct, homologous to the TPR domain involved in peptide
recognition, is critical for substrate binding (Zhang et al., 2012).
However, several studies called the “substrate-binding” capacity
of Nct into question: mutation of mouse Nct-Glu332 (equiva-
lent to human Glu333) to alanine or glutamine was reported
to hinder assembly of the γ-secretase complex but not its spe-
cific activity, suggesting that substrate recognition/binding was
not affected (Chávez-Gutiérrez et al., 2008). Furthermore, Nct-
independent, L-685,458 specific, γ-secretase activity has since
been detected in two separate MEF lines, suggesting that Nct
is in fact not required for substrate recognition (Zhao et al.,
2010). These results support Nct’s role in complex assembly and
maturation, but not substrate recognition. A subsequent study
reexamined the role of Nct and Glu333 in substrate recogni-
tion, overturning the previous finding and suggesting once again
that Nct is indeed involved in substrate binding (Dries et al.,
2009).
While Nct’s role as the substrate-binding subunit of γ-secretase
may be controversial, its importance in γ-secretase regulation
is uncontested: mutation of two conserved cysteine residues
to serine (C213S and C230S) in Nct’s ectodomain resulted in
differential γ-secretase processing of APP and Notch in MEF
cells lacking endogenous Nct. In particular, APP processing was
reduced compared to Notch, suggesting that Nct plays a role
in substrate selectivity, although the exact mechanism was not
identified (Pamrén et al., 2011). Furthermore, synthetic anti-
Nct antibodies were shown to impact substrate selectivity by
changing γ-secretase sub-cellular localization (Zhang et al., 2014).
Quite possibly Nct regulates γ-secretase activity, and particularly
substrate selectivity, through a variety of mechanisms including
direct substrate binding, complex formation/stabilization, matu-
ration, and trafficking.
APH-1
Aph-1, a ∼29 kDa protein with seven TMDs, was discovered
in the same genetic screen as Pen-2 (Francis et al., 2002). The
GXXXG motif of Aph-1’s TMD4 is crucial for assembly into the
γ-secretase complex as it plays a major role in intramembrane
helix-helix interactions. Mutation of Gly123 and Gly122 to aspar-
tic acid in C. elegans and humans, respectively, results in a loss-of-
function phenotype (LOF). The C. elegans LOF phenotype gave
Aph-1 its name: anterior-pharynx-defective (Goutte et al., 2002).
In mammals, mutation of Gly122 to aspartic acid renders Aph-
1 incapable of associating with the γ-secretase complex, thereby
leading to deficiency in Notch cleavage (Lee et al., 2004).
Humans have two Aph-1 genes that give rise to three ver-
sions of the Aph-1 protein (Aph-1aS, Aph-1aL, Aph-1b) due to
alternative splicing of the Aph-1a gene (Shirotani et al., 2004).
Rodents have an additional isoform, Aph1c, which is a dupli-
cation of the Aph-1b gene. Aph-1 isoforms have been reported
to differ in their production of longer and shorter Aβ peptides.
Particularly, when Aph-1a, Aph-1b, and Aph-1c were individually
reintroduced into an Aph1-a−/−b−/−c−/− mouse, Aph1a rescue
of γ-secretase activity resulted in production of shorter Aβ pep-
tides while Aph-1b and Aph-1c rescue led to formation of longer
Aβ species. A potential mechanism for this variability may stem
from the structural changes evident in PS upon binding to one or
the other Aph isoform: fluorescence lifetime imaging microscopy
showed that PS may adopt a more closed conformation upon
binding to Aph-1b compared to its more open conformation
when in complex with Aph-1a (Serneels et al., 2009). This data
implies that the choice to incorporate one Aph1 isoform over
another can have a profound impact on Aβ production and
plaque formation.
γ-SECRETASE IS REGULATED BY MODULATORY PROTEINS
γ-Secretase is regulated not only by its four essential subunits,
but also by other pathways and proteins, many of which have
been identified through LCMS analysis (Teranishi et al., 2010,
2012; Frykman et al., 2012). However, it is unclear whether most
of these alleged γ-secretase-interacting partners actually bind the
active complex and impact γ-secretase activity. Two γ-secretase-
interacting partners, GSAP and Hif-1α, have been reproducibly
shown to bind active γ-secretase and modulate γ-secretase activ-
ity, rendering them both biologically interesting and potentially
clinically relevant. Here we describe what is known about the roles
these “nonessential” γ-secretase subunits play in regulation.
GSAP
GSAP is a ∼98 kDa holoprotein whose ∼16 kDa processed
fragment was identified as a γ-secretase-interacting partner. The
story began when GSAP was implicated in the mechanism by
which imatinib (Gleevec) selectively lowers Aβ without affect-
ing Notch cleavage: a photoactivatable form of imatinib specif-
ically labeled GSAP and not any of the γ-secretase subunits.
Further investigation revealed that GSAP may form a complex
with γ-secretase and APP-CTF, thereby imparting γ-secretase
with substrate specificity for APP over Notch. GSAP RNAi mice
crossed with double transgenic APPswe and PS1∆E9 AD model
mice presented a reduced Aβ burden (He et al., 2010). However,
a subsequent study questioned GSAP’s role in γ-secretase regula-
tion, reporting that GSAP does not interact with APP-CTF and
does not enhance Aβ production in cells or in vitro (Hussain
et al., 2013). The recent finding that imatinib does in fact regulate
GSAP levels and γ-secretase activity supports GSAP’s role as a
γ-secretase modulator (Chu et al., 2014). Furthermore, a SNP
in GSAP has been found to associate with AD, revealing a new
potential risk factor for the disease (Zhu et al., 2014). Taken
together, the data provide strong evidence for GSAP’s role in
modulating Aβ production, but the precise mechanism by which
this occurs needs to be further investigated. GSAP’s function
in Aβ formation is the topic of an ongoing debate (Alzforum,
2014).
Hif-1α
Hif-1α, a ∼93 kDa protein, is a master regulator of cellular
response to hypoxia. While Hif-1α’s properties as a transcrip-
tion factor and role in Notch signaling are well documented
(Gustafsson et al., 2005; Mukherjee et al., 2011; Wang et al.,
2011), its role in γ-secretase regulation was recently discovered:
Hif-1α directly binds to γ-secretase, stimulating its activity for
Notch cleavage. Data show that hypoxic conditions enhance
γ-secretase cleavage of Notch in a Hif-1α-dependent manner.
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Furthermore, it appears that the mechanism for γ-secretase
activation is through a shift in equilibrium from inactive to
active complexes upon Hif-1α binding, suggesting that Hif-1α
has the capacity to turn an inactive γ-secretase into an active
one (Villa et al., 2014). This is a common form of enzymatic
regulation in which the enzyme is abundant in the cell in its
“off ” state and can be quickly mobilized should an “on” signal
appear. Hif-1α studies presented the first evidence for the cell’s
ability to activate γ-secretase complexes that were previously
inactive, and for γ-secretase’s subjugation to temporal regulation
(Figure 3).
γ-SECRETASE IS REGULATED VIA ITS SUBSTRATE, APP
APP proteolysis falls into one of two pathways: either APP is
cleaved sequentially by α and γ-secretase in the nonamyloido-
genic pathway, or it is cleaved by β and γ-secretase in the
amyloidogenic pathway. α-Secretase cleavage of APP occurs in
the Aβ region, which precludes Aβ production, so the choice
to preferentially undergo more α cleavage can mean the dif-
ference between healthy and disease states. What factors deter-
mine the decision to participate in one pathway over the
other? It has been suggested that α-secretase competes with
β-secretase for the APP substrate, thereby lowering Aβ forma-
tion (Lammich et al., 1999; Skovronsky et al., 2000; Postina
et al., 2004). However, compelling evidence exists for an alter-
nate mechanism in which α-secretase cleavage results in for-
mation of a substrate inhibitory domain (ASID) within αCTF
that binds to an allosteric site in γ-secretase, thereby inhibiting
γ-secretase processing of βCTF and ultimate Aβ production. In
this model, α-secretase plays a dual anti-amyloidogenic role: first,
it cleaves APP in the Aβ region, thereby directly precluding Aβ
formation, and second, it initiates a feedback loop in which
αCTF binds γ-secretase and acts as a γ-secretase modulator
which specifically lowers Aβ production (Tian et al., 2010b).
ASID is also present in βCTF, suggesting that the product of
β-secretase cleavage is imbued with γ-secretase-regulating capac-
ity as well. The Flemish FAD mutation, located in the ASID
domain, interferes with βCTF’s inhibitory potency, leading to
increased Aβ (Tian et al., 2010a). ASID is the first example
of a substrate’s inherent ability to regulate γ-secretase, but it
is probably not the last (reviewed in Zhang and Xu, 2010)
(Figure 4).
CONCLUSION
γ-Secretase is regulated at many levels, including but not
limited to regulation by “essential” subunits, complex formation,
“nonessential” subunits, substrates, and lipid composition
(Holmes et al., 2012; Walter and Van Echten-Deckert, 2013).
Although the importance of PS in γ-secretase activity is
well established, it appears that the other essential subunits
also notably contribute to regulating activity and substrate
specificity beyond just their roles in complex assembly.
Furthermore, nonessential subunits like GSAP and Hif-1α
fine-tune modulation of the already stringently-regulated
enzyme, thereby presenting potential therapeutic opportunities
for modulating γ-secretase activity without the mechanism-
based toxicities that result from γ-secretase inhibition
(i.e., GSIs).
Currently, GSMs are being developed as a promising treatment
for AD (Crump et al., 2013) and animal studies indicate that they
FIGURE 3 | Modulatory-protein-based regulation of γ-secretase.
Hif-1α, a master regulator of cellular response to hypoxia, is a
γ-secretase interacting partner. In the presence of sufficient oxygen, no
Hif-1α is produced. However, in oxygen-deficient conditions, Hif-1α is
upregulated. Hif-1α binding to γ-secretase enhances γ-secretase activity
by increasing the ratio of active:inactive γ-secretase complexes in the
cell, thereby increasing γ-secretase cleavage of its substrates, such as
APP and Notch. The implication is twofold: first, inactive γ-secretase
complexes are physiologically important, and second, γ-secretase can
be temporally regulated.
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FIGURE 4 | Substrate-based regulation of γ-Secretase. α or β-secretase
cleave amyloid precursor protein to generate αCTF or βCTF, respectively.
αCTF and βCTF, which are γ-secretase substrates, can then interact with
γ-secretase to form a substrate-enzyme complex. The substrate inhibitory
domain (ASID) in αCTF and βCTF interacts with γ-secretase in a location
distinct from both the active site and the substrate binding site of the
enzyme. Binding of αCTF to γ-secretase results in a low-productivity
complex: the ASID in αCTF inhibits γ-secretase activity for Aβ production.
ASID in βCTF is a less potent inhibitor of γ-secretase. The implication is that
α-secretase cleavage potentiates γ-secretase inhibition by at least two
mechanisms: first, α-secretase cleaves APP in the middle of the Aβ region,
precluding Aβ formation, and second, α-secretase cleavage results in
formation of αCTF, which inhibits γ-secretase activity through its ASID.
γ-Secretase cleavage of αCTF produces p3 and cleavage of βCTF produces
the amyloidogenic Aβ.
could provide advantages over GSIs (Mitani et al., 2012; Rogers
et al., 2012). Other Aβ-based therapies, such as immunotherapy
and autophagic restoration, are being explored for AD as well
(Lemere, 2013; Li et al., 2013). In addition to mice (Eimer and
Vassar, 2013; Veeraraghavalu et al., 2013), other models have been
investigated for AD studies (Mccoll et al., 2012; Do Carmo and
Cuello, 2013), which help to elucidate the role of γ-secretase
in pathogenesis. Recently, it has been suggested that a set of
γ-secretase product peptides in the cerebrospinal fluid may serve
as biomarkers for AD (Hata et al., 2012; Rosén et al., 2013). No
doubt, developing a better understanding of γ-secretase in AD
pathogenesis will facilitate the discovery of effective biomarkers
and safe treatments. The complex levels of γ-secretase regula-
tion that are now emerging may improve our ability to develop
targeted therapies for AD and cancer.
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